Tasly subsidiary secures approval for Torsemide injection drug

Tasly Pharmaceutical Group (SSE:600535) announced that its subsidiary, Jiangsu Tasly Di Yi Pharmaceutical, has been granted a drug registration certificate from the National Medical Products Administration for Torsemide Injection, indicated for conditions requiring rapid diuresis such as congestive heart failure and liver cirrhosis. The drug will be produced by Chengdu Haitong Pharmaceutical. According to the announcement, the total research and development investment for this drug by Jiangsu Di Yi amounted to CNY 3.66 million. Tasly emphasized that while this approval enriches its cardiovascular and metabolic product portfolio, the future market performance of the drug remains subject to market uncertainties and regulatory factors. Torsemide Injection originally launched in the EU in 1991 but is not yet registered by the original company. According to Menet data, the drug generated CNY 407 million in sales.